Quick Answer
AN2 Therapeutics, Inc. reported Net Income of -$35.17 million for fiscal year 2025.
AN2 Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$35.17M +31.5% |
-$51.32M +20.7% |
-$64.73M -58.1% |
-$40.96M -90.1% |
-$21.54M | — |
| Diluted EPS | -$1.16 +32.6% |
-$1.72 +37.2% |
-$2.74 +1.8% |
-$2.79 +73.8% |
-$10.64 | — |
| Total Assets | $61.95M -32.7% |
$92.09M -33.6% |
$138.74M +35.3% |
$102.56M +57.0% |
$65.32M | — |
| Cash and Equivalents | $19.94M -6.6% |
$21.35M +36.5% |
$15.65M -42.5% |
$27.22M +125.0% |
$12.10M | — |
| Stockholders Equity | $53.06M -35.2% |
$81.85M -34.4% |
$124.70M +30.8% |
$95.37M +301.2% |
-$47.41M -133.3% |
-$20.32M |
| R&D Expense | $24.77M -38.8% |
$40.49M -26.2% |
$54.87M +92.5% |
$28.51M +76.5% |
$16.16M | — |
| Operating Income | -$38.11M +32.9% |
-$56.79M +18.4% |
-$69.64M -64.8% |
-$42.26M -95.9% |
-$21.57M | — |
| Shares Outstanding | 27.41M -8.4% |
29.92M +0.6% |
29.74M +53.3% |
19.40M +610.6% |
2.73M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$9.35M | +26.6% | -44.7% |
| Diluted EPS | September 30, 2025 | -$0.31 | +27.9% | -47.6% |
| Total Assets | September 30, 2025 | $67.23M | -31.2% | -11.3% |
| Cash and Equivalents | September 30, 2025 | $18.00M | -46.3% | -1.2% |
| Stockholders Equity | September 30, 2025 | $60.38M | -31.1% | -12.3% |
| R&D Expense | September 30, 2025 | $7.00M | -15.5% | +118.8% |
| Operating Income | September 30, 2025 | -$10.04M | +28.4% | -39.1% |
| Shares Outstanding | September 30, 2025 | 27.37M | -8.4% | -0.0% |
- AN2 Therapeutics, Inc. reported Net Income of -$35.17 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed an increase of +31.5% in Net Income compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Diluted EPS of $1.16 per share (loss) for fiscal year 2025.
- AN2 Therapeutics, Inc. showed an increase of +32.6% in Diluted EPS compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Total Assets of $61.95 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed a decrease of -32.7% in Total Assets compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Cash and Equivalents of $19.94 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed a decrease of -6.6% in Cash and Equivalents compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Stockholders Equity of $53.06 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed a decrease of -35.2% in Stockholders Equity compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported R&D Expense of $24.77 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed a decrease of -38.8% in R&D Expense compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Operating Income of -$38.11 million for fiscal year 2025.
- AN2 Therapeutics, Inc. showed an increase of +32.9% in Operating Income compared to the prior fiscal year.
- AN2 Therapeutics, Inc. reported Shares Outstanding of 27.41 million shares for fiscal year 2025.
- AN2 Therapeutics, Inc. showed a decrease of -8.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: